Migraine, a multifactorial neurological disorder, manifests in various forms, each presenting distinct challenges in diagnosis and management. This comprehensive review delves into the intricacies of migraine subtypes, elucidates their clinical features, diagnostic criteria, and explores a plethora of treatment options to guide healthcare providers in delivering personalized care.

Introduction: With its intricate interplay of genetic, environmental, and neurobiological factors, migraine stands as one of the most prevalent and disabling neurological disorders globally. Understanding the nuances of its diverse subtypes and tailoring treatment strategies accordingly is paramount for alleviating the burden it imposes on individuals and society at large. This review aims to unravel the complexities of migraine classification, symptomatology, diagnostic criteria, and therapeutic interventions to empower clinicians in their approach to migraine care.

Types of Migraines:

1. Migraine without Aura (Common Migraine):
   • Characterized by recurrent, pulsating headaches typically lasting 4 to 72 hours.
   • Often unilateral and aggravated by routine physical activity.
   • Accompanied by symptoms such as nausea, vomiting, photophobia, and phonophobia.
   • Diagnosis relies on the absence of aura phenomena.
2. Migraine with Aura (Classic Migraine):
   • Preceded or accompanied by transient neurological disturbances known as aura.
   • Aura manifestations encompass visual disturbances (e.g., scotomas, zigzag lines), sensory changes, language disturbances, or motor deficits.
   • Aura typically resolves before or coincides with the onset of headache.
3. Chronic Migraine:
   • Defined by headaches occurring on 15 or more days per month for at least 3 months, with features of migraine on at least 8 days per month.
   • Often associated with medication overuse and significant functional impairment.
   • Differential diagnosis crucial to distinguish from other chronic headache syndromes.
4. Menstrual Migraine:
   • Headaches manifesting in a cyclic pattern related to the menstrual cycle.
   • Predominantly estrogen-dependent, occurring most commonly in the perimenstrual phase.
   • Treatment may involve hormonal interventions or prophylactic migraine therapy tailored to the menstrual cycle.
5. Hemiplegic Migraine:
   • Rare subtype characterized by reversible motor weakness or paralysis affecting one side of the body.
   • Accompanied by other aura symptoms and occasionally associated with familial hemiplegic migraine (FHM) genetic mutations.
   • Requires careful evaluation to differentiate from other neurological emergencies such as stroke.

Diagnostic Criteria for Migraine:

• According to the International Classification of Headache Disorders (ICHD), migraine diagnosis requires:
  1. At least five attacks fulfilling the following criteria:
  2. Headache lasting 4-72 hours (untreated or unsuccessfully treated)
  3. At least two of the following: unilateral location, pulsating quality, moderate to severe pain intensity, aggravation by or causing avoidance of routine physical activity
  4. During headache, at least one of the following: nausea and/or vomiting, photophobia, and phonophobia
  5. Not better accounted for by another diagnosis

Treatment Modalities:

1. Acute Treatment:
   • Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen for mild to moderate attacks.
   • Triptans (e.g., sumatriptan, rizatriptan), serotonin receptor agonists, as first-line agents for moderate to severe migraines.
   • Combination medications (e.g., sumatriptan-naproxen) for enhanced efficacy in certain cases.
   • Antiemetics such as metoclopramide or prochlorperazine for associated nausea and vomiting.
2. Preventive Treatment:
   • Beta-blockers (e.g., propranolol), calcium channel blockers (e.g., verapamil), and tricyclic antidepressants (e.g., amitriptyline) as first-line agents for migraine prophylaxis.
   • Antiepileptic drugs (e.g., topiramate, valproate) for patients with frequent or refractory migraines.
   • Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor (e.g., eptinezumab, fremanezumab) for chronic migraine prophylaxis in adults.
   • OnabotulinumtoxinA injections approved for chronic migraine prophylaxis.
3. Non-Pharmacological Approaches:
   • Lifestyle modifications encompassing stress management techniques, regular exercise, and optimization of sleep hygiene.
   • Psychological interventions such as cognitive-behavioral therapy (CBT) and relaxation techniques to address comorbid anxiety and depression.
   • Alternative therapies including biofeedback, acupuncture, and transcutaneous supraorbital nerve stimulation (tSNS) as adjunctive or standalone treatments.

Conclusion: The management of migraine necessitates a comprehensive understanding of its diverse manifestations, adherence to diagnostic criteria, and individualized treatment strategies tailored to patient-specific factors. By embracing a multifaceted approach that integrates pharmacological and non-pharmacological interventions, healthcare providers can strive towards optimizing outcomes and enhancing the quality of life for individuals grappling with the profound impact of migraine. Ongoing research endeavors aimed at unraveling the pathophysiological mechanisms underlying migraine and identifying novel therapeutic targets hold promise for further advancing migraine care in the future.